what will the sp be in feb?, page-6

Something to consider regarding customer orders for 1ml is that they may not meet expectation. UNI has already flagged that they may find it difficult to generate substantial sales of their 1ml until they have the additional clinical range products in production(3ml & 5ml).

Reading on VanishPoints commercial progress, they have found it very difficult to penetrate the clinical market, as potential customers are forbidden to even discuss their product under the terms of their existing supply agreement (I assume its with BD). We have a far superior product to any existing ready-to-fill syringe, but when you look at vanish points product, I am not so sure our product will be superior to theirs in the clinical range? Please provide your own substantiated opinion on this.

So, my thoughts are, we will see SA & UNI reach a positive agreement of which drugs will be supplied, it will be a good outcome for UNI. We may see an additional pharma sign up to the RTFS, but it will be with lower forecast orders than predicted. The 1ml sales will dissapoint due to the reasons outlined above, which will temper the excitement that remains surrounding the potential of the RTFS.

So, price target of $1.20 by the end of February assuming all this news is released by that date.